Welcome to the e-CCO Library!

OP33: Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme
Year: 2022
Source: ECCO'22
Authors: Colombel, J.F.(1);Cao, Q.(2);Ghosh, S.(3);Reinisch, W.(4);Zhou, W.(5);Ilo, D.(5);Shu, L.(5);Yao, X.(6);Rubin, D.T.(7);
Created: Friday, 11 February 2022, 3:52 PM
OP33: Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella study
Year: 2021
Source: ECCO'21 Virtual
Authors: Sandborn, W.(1);Danese, S.(2);Leszczyszyn, J.(3);Romatowski, J.(4);Altintas, E.(5);Peeva, E.(6);Vincent, M.(6);Reddy, P.(7);Banfield, C.(7);Banerjee, A.(7);Gale, J.(6);Hung, K.(6)
Created: Wednesday, 2 June 2021, 4:12 PM
OP33: Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO)
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Raine, T.(1)*;Vaja, S.(2);Subramanian, S.(1);Brezina, B.(1);Probert, C.S.(3);Steel, A.(3);Lofthouse, M.(3);Speight, R.A.(4);Lamb, C.(4);Sebastian, S.(5);Kane, J.(5);Thut, J.(5);Din, S.(6);Arnott, I.(6);Smith, L.(6);Galea, J.(7);Hendy, P.(8);Flores, L.(9);Selinger, C.(10);Onoviran, F.(10);Steed, H.(11);Green, M.(12);Williams, J.(13);Jairath, V.(14);Qian, W.(2);Pavey, H.(2);Champion, K.(2);Dowling, F.(2);Thomas, M.(2);Wolf, K.(2);Davis-Wilkie, C.(2);Parkes, M.(1);Kaser, A.(15);
Created: Friday, 14 July 2023, 10:43 AM
OP34 Whole blood profiling of T-cell-derived miRNA allows the development of prognostic models in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Kalla1, A. Adams2, R. White3, C. Clarke4, A. Ivens3, N. Ventham5, N. Kennedy6, S. McTaggart7, I. IBD Character Consortium8, G.T. Ho1, A. Buck3, J. Satsangi2, IBD Character Consortium

Created: Thursday, 30 January 2020, 10:12 AM
OP34: AJM300, an Oral Antagonist of α4-Integrin, as induction therapy for patients with Moderately Active Ulcerative Colitis: A Phase 3, randomized, double-blind, placebo-controlled induction study
Year: 2021
Source: ECCO'21 Virtual
Authors: Watanabe, M.(1);Matsuoka, K.(2); Ohmori, T.(3);Nakajima, K.(4);Ishida, T.(5);Ishiguro , Y.(6);Kanke, K.(7);Kobayashi, K.(8);Hirai, F.(9);Watanabe, K.(10);Hibi, T.(11)
Created: Wednesday, 2 June 2021, 4:12 PM
OP34: Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis
Year: 2022
Source: ECCO'22
Authors: Panaccione, R.(1);Collins, E.B.(2);Melmed, G.Y.(3);Vermeire, S.(4);Danese, S.(5);Higgins, P.D.R.(6);Zhou, W.(7);Ilo, D.(7);Sharma, D.(7);Sanchez Gonzalez, Y.(7);Wang, S.T.(2);
Created: Friday, 11 February 2022, 3:52 PM
OP34: Enteral Nutrition Compared with Steroids in Children with Crohn's Disease – In Israel: a nationwide study from the epi-IIRN
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Plotkin, L.(1)*;Lujan, R.(1);Focht, G.(1);Greenfeld, S.(2);Loewenberg Weisband, Y.(3);Lederman, N.(4);Matz, E.(5);Dotan, I.(6);Turner, D.(1);
Created: Friday, 14 July 2023, 10:43 AM
OP34: VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitis
Year: 2019
Source: ECCO '19 Copenhagen
Authors:

Stefan. Schreiber1, Laurent. Peyrin-Biroulet2, Edward. V. LoftusJr.3, Silvio. Danese4, Jean-Frederic. Colombel5, Brihad. Abhyankar6, Jingjing. Chen7, Raquel. Rogers7, Richard. A. Lirio7, Jeffrey. D. Bornstein7, Bruce. E. Sands5

Created: Thursday, 28 February 2019, 8:13 AM
OP35 Treatment outcomes of inflammatory bowel disease in the biological era—a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Zhao1, M. Lördal2, E. Langholz3, T. Knudsen4, M. Voutilainen5, M.L. Høivik6, B. Moum6, B. Saebo7, P. Haiko8, C. Malmgren9, M. Coskun10, H.O. Melberg11, J. Burisch12

Created: Thursday, 30 January 2020, 10:12 AM
OP35: Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Danese, S.(1);Vermeire, S.(2);D’Haens, G.(3);Panés, J.(4);Dignass, A.(5);Magro, F.(6,7);Nazar, M.(8);Le Bars, M.(9);Lahaye, M.(10);Ni, L.(11);Bravatà, I.(12);Gaya, D.R.(13);Peyrin-Biroulet, L.(14)
Created: Wednesday, 2 June 2021, 4:12 PM
OP35: Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: FeaganSenior Scientific Officer, B.G.(1)*;Matsuoka, K.(2);Rogler, G.(3);Faes, M.(4);Oortwijn, A.(5);de Haas, A.(6);Rudolph, C.(5);Peyrin-Biroulet, L.(7);
Created: Friday, 14 July 2023, 10:43 AM
OP35: Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Yzet1, R. Ungaro*2, P. Bossuyt3, F. Baert4, T. Vanasek5, G. D’Haens6, V. Joustra6, R. Panaccione7, G. Novacek8, A. Armuzzi9, O. Golovchenko10, O. Prymak10, A. Goldis11, S. Travis12, X. Hébuterne13, M. Ferrante14, G. Rogler15, M. Fumery1, S. Danese16, G. Rydzewska17, B. Pariente18, E. Hertervig19, C. Stanciu20, J-C. Grimaud21, M-M. Diculescu22, L. Peyrin-Biroulet23, D. Laharie24, J. P. Wright25, F. Gomollón26, I. Gubonina27, S. Schreiber28, S. Motoya29, P. Hellström30, J. Halfvarson31, J-F. Colombel2

Created: Friday, 22 February 2019, 9:41 AM
OP35: Natural history of anal ulcerations in pediatric-onset Crohn's Disease: A population-based study
Year: 2022
Source: ECCO'22
Authors: Mortreux, P.(1);Leroyer, A.(2);Dupont, C.(3);Ley, D.(4);Bertrand, V.(5);Spyckerelle, C.(6);Guillon, N.(2);Desreumaux, P.(1);Gower-Rousseau, C.(2);Savoye, G.(7);Fumery, M.(8);Turck, D.(4);Siproudhis, L.(9);Sarter, H.(2);
Created: Friday, 11 February 2022, 3:52 PM
OP36 Investigating the role of bioactives produced by gut bacteria to modulate immune response in inflammatory bowel disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

R. Giri1,2, K. Shamsunnahar3, A. Salim3, R. Capon3, M. Morrison4, P. O Cuiv4, J. Begun1,2

Created: Thursday, 30 January 2020, 10:12 AM
OP36: A colonic gene expression signature predicts non-response to anti-inflammatory therapies in inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Sato*1, K. Li1, K. Hayden1, L. Tomsho1, F. Baribaud1, C. Brodmerkel1, L. E. Greenbaum1, J. R. Friedman1, M. Curran1, Y. Imai2, S. Plevy1, S. E. Telesco1

Created: Friday, 22 February 2019, 9:41 AM
OP36: Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study
Year: 2022
Source: ECCO'22
Authors: Sands, B.E.(1);Feagan, B.G.(2);Sandborn, W.J.(3);Shipitofsky, N.(4);Marko, M.(4);Sheng, S.(4);Johanns, J.(4);Germinaro, M.(4);Vetter, M.(4);Panés, J.(5);
Created: Friday, 11 February 2022, 3:52 PM
OP36: Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bokemeyer, B.(1,2,3)*;Plachta-Danielzik, S.(3);Deppe, H.(4);Mohl, W.(5);Teich, N.(6);Hoffstadt, M.(7);Schweitzer, A.(8);von der Ohe, M.(9);Gauss, A.(10);Atreya, R.(11);Krause, T.(12);Blumenstein, I.(13);Fajardo Salmon, S.(3);Hartmann, P.(4);Gilman, E.(3);Schreiber, S.(3,14);
Created: Friday, 14 July 2023, 10:43 AM
OP36: Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Year: 2021
Source: ECCO'21 Virtual
Authors: Bossuyt, P.(1);Ferrante, M.(2);Baert, F.(3);Danese, S.(4);Feagan, B.G.(5);Loftus Jr, E.V.(6);Panés, J.(7);Peyrin-Biroulet, L.(8);Ran, Z.(9);Armuzzi, A.(10);D’Haens, G.R.(11);SONG, A.(12);Neimark, E.(12);Liao, X.(12);Zhou, Q.(12);Berg, S.(12);Wallace, K.(12);Panaccione, R.(13)
Created: Wednesday, 2 June 2021, 4:12 PM
OP37 Fibrogenesis in chronic DSS colitis is driven by an innate lymphoid cell-independent innate immune response
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. Creyns1,2, J. Cremer1,2, G. De Hertogh3, L. Boon4, M. Ferrante2,5, S. Vermeire2,5, G. Van Assche2,5, J. Ceuppens1, C. Breynaert1,6, Allergy and Clinical Immunology Research Group

Created: Thursday, 30 January 2020, 10:12 AM
OP37: Bacterial suppression of intestinal fungi via activation of human gut Vδ2+ T-cells
Year: 2022
Source: ECCO'22
Authors: Mathew, L.(1);Savage, M.(1);Pardieu, C.(1);O'Brien, M.(1);Sze, S.K.(2);Eberl, M.(3);Stagg, A.(1);Gasparetto, M.(4);Kok, K.(4);Lindsay, J.(4);McCarthy, N.(1);
Created: Friday, 11 February 2022, 3:52 PM